TARS on Nasdaq
Tarsus Pharmaceuticals, Inc.
In its 2026 annual report the company says: “We are a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care.”3 It is headquartered in Irvine, California.1 Its shares trade on Nasdaq under the symbol TARS.1
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with Immunocore, ADMA Biologics (United States) or Krystal Biotech, Inc., or pick any stock.
- TickerTARS on Nasdaq1
- IndustryBiological Products, (No Diagnostic Substances)1
- HeadquartersIrvine, California1
- Incorporated inDE2
- Business address15440 Laguna Canyon Road, Irvine, Ca 926182
- Filer categoryLarge accelerated filer2
See how the biggest companies compare on our leaderboards
We are a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. We launched XDEMVY ® (lotilaner ophthalmic solution) 0.25%, formerly known as TP-03, for the treatment of Demodex blepharitis, in August 2023 after receiving U.S. Food and Drug Administration (“FDA”) approval in July 2023. Demodex blepharitis is caused by the infestation of Demodex mites. Demodex blepharitis (“blephar” is a reference to eyelid and “itis” is a reference to inflammation) is a disease characterized by inflammation of the eyelid margin, redness and ocular irritation, including a specific type of eyelash dandruff called collarettes, which are pathognomonic for Demodex blepharitis. Poorly controlled and progressive Demodex blepharitis can lead to corneal damage over time and, in extreme cases, blindness. There may be as many as approxima…3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-15.7%Operating margin4
-14.7%Net margin4
146.7%Revenue growth, 20254
-19.3%Return on equity4
0.21×Debt to equity4
-$22.3MFree cash flow4
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development13¢$64.3M
- Selling, general and admin87¢$427.3M
- Income tax0¢$2.1M
Out of $451.4M in revenue.4 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total revenues | $451.4M | $183.0M | $17.4M |
| Research and development | $64.3M | $53.4M | $50.3M |
| Selling, general and administrative | $427.3M | $237.3M | $108.7M |
| Total operating expenses | $522.3M | $303.5M | $160.6M |
| Loss from operations before other income (expense) | -$71.0M | -$120.6M | -$143.2M |
| Interest income | $15.7M | $15.0M | $10.3M |
| Interest expense | -$8.9M | -$7.8M | -$3.3M |
| Loss on debt extinguishment | $0 | -$1.9M | $0 |
| Other income (expense), net | -$202.0K | -$206.0K | $274.0K |
| Total other income, net | $6.6M | $5.0M | $7.3M |
| Loss before income taxes | -$64.4M | -$115.6M | -$135.9M |
| Provision for income taxes | -$2.1M | $0 | $0 |
| Net loss | -$66.4M | -$115.6M | -$135.9M |
| Unrealized gain (loss) on marketable securities and cash equivalents | $202.0K | $181.0K | $72.0K |
| Comprehensive loss | -$66.2M | -$115.4M | -$135.8M |
| Net loss per share, basic (usd per share) | -$1.59 | -$3.07 | -$4.62 |
| Net loss per share, diluted (usd per share) | -$1.59 | -$3.07 | -$4.62 |
| Weighted-average shares outstanding, basic (in shares) | 41.8M shares | 37.6M shares | 29.4M shares |
| Weighted-average shares outstanding, diluted (in shares) | 41.8M shares | 37.6M shares | 29.4M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 5 fiscal years (annual) or 5 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2024-03-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | $183.6M | $94.8M | |||
| Restricted cash | $560.0K | $0 | |||
| Marketable securities | $233.6M | $196.6M | |||
| Accounts receivable, net | $85.1M | $46.8M | |||
| Inventory | $4.4M | $2.6M | |||
| Other receivables | $2.1M | $1.3M | |||
| Prepaid expenses | $13.5M | $14.7M | |||
| Total current assets | $522.8M | $356.7M | |||
| Restricted cash, non-current | $2.0M | $2.6M | |||
| Inventory, non-current | $2.5M | $2.5M | |||
| Property and equipment, net | $11.7M | $2.3M | |||
| Intangible assets, net | $7.4M | $8.3M | |||
| Operating lease right-of-use assets | $10.1M | $552.0K | |||
| Long-term investments | $3.9M | $3.0M | |||
| Other assets | $1.9M | $999.0K | |||
| Total assets | $562.2M | $377.0M | |||
| Accounts payable | $16.4M | $9.4M | |||
| Accrued payroll and benefits | $17.8M | $15.8M | |||
| Other accrued liabilities | $101.5M | $55.4M | |||
| Total current liabilities | $135.7M | $80.6M | |||
| Long-term debt, net | $72.4M | $71.8M | |||
| Other long-term liabilities | $10.6M | $0 | |||
| Total liabilities | $218.7M | $152.5M | |||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding | $0 | $0 | |||
| Common stock, $0.0001 par value; 200,000,000 shares authorized; 42,553,931 shares issued and outstanding at December 31, 2025; 38,349,826 shares issued and outstanding at December 31, 2024 | $6.0K | $6.0K | |||
| Additional paid-in capital | $769.7M | $584.6M | |||
| Accumulated other comprehensive income (loss) | $381.0K | $179.0K | |||
| Accumulated deficit | -$426.6M | -$360.2M | |||
| Total stockholders equity | $343.4M | $224.5M | $197.0M | $192.9M | |
| Total liabilities and stockholders equity | $562.2M | $377.0M | |||
| Preferred stock, par value (usd per share) | $0.00 | $0.00 | |||
| Preferred stock, authorized (in shares) | 10.0M shares | 10.0M shares | |||
| Preferred stock, issued (in shares) | 0 shares | 0 shares | |||
| Preferred stock, outstanding (in shares) | 0 shares | 0 shares | |||
| Common stock, par value (usd per share) | $0.00 | $0.00 | $0.00 | ||
| Common stock, authorized (in shares) | 200.0M shares | 200.0M shares | |||
| Common stock, issued (in shares) | 42.6M shares | 38.3M shares | |||
| Common stock, outstanding (in shares) | 42.6M shares | 38.3M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2024-03-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | $183.6M | $94.8M | |||
| Restricted cash | $560.0K | $0 | |||
| Marketable securities | $233.6M | $196.6M | |||
| Accounts receivable, net | $85.1M | $46.8M | |||
| Inventory | $4.4M | $2.6M | |||
| Other receivables | $2.1M | $1.3M | |||
| Prepaid expenses | $13.5M | $14.7M | |||
| Total current assets | $522.8M | $356.7M | |||
| Restricted cash, non-current | $2.0M | $2.6M | |||
| Inventory, non-current | $2.5M | $2.5M | |||
| Property and equipment, net | $11.7M | $2.3M | |||
| Intangible assets, net | $7.4M | $8.3M | |||
| Operating lease right-of-use assets | $10.1M | $552.0K | |||
| Long-term investments | $3.9M | $3.0M | |||
| Other assets | $1.9M | $999.0K | |||
| Total assets | $562.2M | $377.0M | |||
| Accounts payable | $16.4M | $9.4M | |||
| Accrued payroll and benefits | $17.8M | $15.8M | |||
| Other accrued liabilities | $101.5M | $55.4M | |||
| Total current liabilities | $135.7M | $80.6M | |||
| Long-term debt, net | $72.4M | $71.8M | |||
| Other long-term liabilities | $10.6M | $0 | |||
| Total liabilities | $218.7M | $152.5M | |||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding | $0 | $0 | |||
| Common stock, $0.0001 par value; 200,000,000 shares authorized; 42,553,931 shares issued and outstanding at December 31, 2025; 38,349,826 shares issued and outstanding at December 31, 2024 | $6.0K | $6.0K | |||
| Additional paid-in capital | $769.7M | $584.6M | |||
| Accumulated other comprehensive income (loss) | $381.0K | $179.0K | |||
| Accumulated deficit | -$426.6M | -$360.2M | |||
| Total stockholders equity | $343.4M | $224.5M | $197.0M | $192.9M | |
| Total liabilities and stockholders equity | $562.2M | $377.0M | |||
| Preferred stock, par value (usd per share) | $0.00 | $0.00 | |||
| Preferred stock, authorized (in shares) | 10.0M shares | 10.0M shares | |||
| Preferred stock, issued (in shares) | 0 shares | 0 shares | |||
| Preferred stock, outstanding (in shares) | 0 shares | 0 shares | |||
| Common stock, par value (usd per share) | $0.00 | $0.00 | $0.00 | ||
| Common stock, authorized (in shares) | 200.0M shares | 200.0M shares | |||
| Common stock, issued (in shares) | 42.6M shares | 38.3M shares | |||
| Common stock, outstanding (in shares) | 42.6M shares | 38.3M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$66.4M | -$115.6M | -$135.9M |
| Depreciation | $855.0K | $685.0K | $744.0K |
| Amortization of intangible assets | $961.0K | $540.0K | $133.0K |
| Amortization/accretion of debt-related costs | $593.0K | $482.0K | $385.0K |
| Stock-based compensation | $41.7M | $27.8M | $19.8M |
| Loss on debt extinguishment | $0 | $1.9M | $0 |
| Non-cash lease expense | $682.0K | $635.0K | $541.0K |
| Net amortization/accretion on marketable securities | -$5.5M | -$4.2M | -$3.2M |
| Realized/unrealized loss (gain) on equity investments | $0 | $591.0K | -$259.0K |
| Change in fair value of equity warrants issued by licensee | $0 | $201.0K | -$117.0K |
| Accounts receivable, net | -$38.3M | -$30.1M | -$16.6M |
| Inventory | -$1.8M | -$2.0M | -$3.1M |
| Other receivables | -$754.0K | -$206.0K | $2.5M |
| Prepaid expenses | $1.7M | -$7.0M | -$2.9M |
| Other non-current assets | -$527.0K | $572.0K | -$718.0K |
| Accounts payable | $6.9M | $2.5M | $4.5M |
| Accrued payroll and benefits | $2.0M | $2.6M | $7.7M |
| Other accrued liabilities | $45.4M | $37.8M | $8.7M |
| Other long-term liabilities | $0 | -$233.0K | $185.0K |
| Net cash used in operating activities | -$12.5M | -$83.0M | -$117.5M |
| Proceeds from sales and maturities of marketable securities | $361.8M | $73.0M | $174.8M |
| Purchases of marketable securities | -$393.2M | -$262.6M | -$28.7M |
| Purchases of long-term investments | -$870.0K | -$3.0M | $0 |
| Intangible asset additions | $0 | -$5.0M | -$4.0M |
| Purchases of property and equipment | -$9.9M | -$1.6M | -$1.5M |
| Net cash (used in) provided by investing activities | -$42.1M | -$199.2M | $140.6M |
| Proceeds from issuance of pre-funded warrants, net of paid issuance costs | $0 | $9.4M | $0 |
| Proceeds from exercise of stock options | $6.3M | $5.6M | $592.0K |
| Proceeds from sale of common stock under employee stock purchase plan | $2.3M | $1.8M | $985.0K |
| Proceeds from long-term debt | $0 | $75.0M | $10.0M |
| Payment of debt issuance costs | $0 | -$3.5M | $0 |
| Payments for debt extinguishment | $0 | -$31.9M | $0 |
| Net cash provided by financing activities | $143.4M | $154.7M | $130.2M |
| Net increase (decrease) in cash, cash equivalents and restricted cash | $88.8M | -$127.6M | $153.3M |
| Operating lease right-of-use asset obtained in exchange for operating lease liability | $10.2M | $384.0K | $1.8M |
| Operating lease modification | $0 | $1.1M | $0 |
| Interest expense paid in cash | $8.3M | $7.7M | $2.9M |
| Additions of property and equipment included within accounts payable and other accrued liabilities | $1.5M | $99.0K | $134.0K |
| Offering costs included within accounts payable | $0 | $21.0K | $0 |
No quarter-by-quarter statement was filed.
Corporate structure
Tarsus Pharmaceuticals, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Tarsus Pharmaceuticals, Inc.
- Janus Henderson Group Ltd. Filed SCHEDULE 13G/A on Tarsus Pharmaceuticals, Inc., latest Aug 13, 2026 (2 filings since May 15, 2026)
- Deep Track Capital, LP Filed SCHEDULE 13G/A on Tarsus Pharmaceuticals, Inc., latest May 15, 2026 (3 filings since Jul 28, 2025)
- Prudential Financial Filed SCHEDULE 13G/A on Tarsus Pharmaceuticals, Inc., latest May 8, 2026 (2 filings since Nov 14, 2024)
- JENNISON ASSOCIATES LLC Filed SCHEDULE 13G/A on Tarsus Pharmaceuticals, Inc., latest May 6, 2026 (2 filings since Nov 12, 2024)
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on Tarsus Pharmaceuticals, Inc., latest Mar 27, 2026 (3 filings since Nov 4, 2024)
- TANG CAPITAL MANAGEMENT LLC Filed SCHEDULE 13G/A on Tarsus Pharmaceuticals, Inc., latest Feb 17, 2026 (2 filings since May 15, 2025)
- RTW INVESTMENTS, LP Filed SCHEDULE 13G/A on Tarsus Pharmaceuticals, Inc., latest Aug 14, 2025 (4 filings since Feb 14, 2022)
- Morgan Stanley Filed SCHEDULE 13G/A on Tarsus Pharmaceuticals, Inc., latest May 7, 2025 (2 filings since Feb 9, 2024)
- BlackRock Filed SCHEDULE 13G/A on Tarsus Pharmaceuticals, Inc., latest Apr 24, 2025 (6 filings since Feb 8, 2023)
- Cowen Financial Products LLC Filed SCHEDULE 13G/A on Tarsus Pharmaceuticals, Inc., latest Feb 13, 2025 (3 filings since May 5, 2023)
- Cormorant Asset Management, LP Filed SC 13G/A on Tarsus Pharmaceuticals, Inc., latest Nov 14, 2024 (4 filings since Feb 14, 2022)
- Paradigm Biocapital Advisors LP Filed SC 13G/A on Tarsus Pharmaceuticals, Inc., latest Nov 14, 2024 (2 filings since Jan 22, 2024)
- Tarsus Pharmaceuticals, Inc. Irvine, California
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Tarsus Pharmaceuticals, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $13.8M4 Dec 31, 2025 | $4.3M4 Dec 31, 2024 | +220.8% |
| Accumulated depreciation | $2.1M4 Dec 31, 2025 | $2.0M4 Dec 31, 2024 | +6.2% |
| Property and equipment, net | $11.7M4 Dec 31, 2025 | $2.3M4 Dec 31, 2024 | +404.1% |
| Operating-lease assets (leased space) | $10.1M4 Dec 31, 2025 | $552.0K4 Dec 31, 2024 | +1726.1% |
Real estate and locations
| Item | Latest | A year before | Change |
|---|---|---|---|
| Area of real estate | 98,807 sq ft4 Dec 31, 2025 | 59,626 sq ft7 Dec 31, 2024 | +65.7% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $183.6M4 Dec 31, 2025 | $94.8M4 Dec 31, 2024 | +93.7% |
| Marketable securities, current | $233.6M4 Dec 31, 2025 | $196.6M4 Dec 31, 2024 | +18.9% |
| Debt securities available for sale | $233.6M4 Dec 31, 2025 | $196.6M4 Dec 31, 2024 | +18.9% |
| Long-term investments | $3.9M4 Dec 31, 2025 | $3.0M4 Dec 31, 2024 | +29.0% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Intangible assets, net (excluding goodwill) | $7.4M4 Dec 31, 2025 | $8.3M4 Dec 31, 2024 | −11.5% |
| Accumulated amortization | $1.6M4 Dec 31, 2025 | $674.0K4 Dec 31, 2024 | +142.4% |
| Finite-lived intangibles, net | $7.4M4 Dec 31, 2025 | $8.3M7 Dec 31, 2024 | −11.5% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $4.4M4 Dec 31, 2025 | $2.6M4 Dec 31, 2024 | +66.9% |
| Raw materials | $07 Dec 31, 2024 | $2.5M7 Dec 31, 2023 | −100.0% |
| Work in process | $1.4M4 Dec 31, 2025 | $614.0K4 Dec 31, 2024 | +129.6% |
| Finished goods | $3.0M4 Dec 31, 2025 | $2.0M4 Dec 31, 2024 | +47.7% |
Properties, in its own words
As of December 31, 2025, the Company had two active leases with combined square footage of 98,807 for office and laboratory suites in Irvine, California. In December 2024, the Company entered into an agreement to terminate its former facility lease agreements and entered into a new lease agreement both with the same landlord, to relocate its corporate headquarters to another location in Irvine, California for a 10-year lease term. In September 2025, the Company gained access to the new facility, and commenced the new lease, however the Company’s headquarters have not yet been relocated. Construction is still in progress on the new facility and the Company plans to move in during 2026. We believe that this space will be sufficient to meet our needs for the foreseeable future and that any additional space we may require will be available on commercially reasonable terms (see Note 9).
Item 2 of the 10-K filed Feb 23, 2026.3
Leadership
Who has led Tarsus Pharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
Chief operating officer
2025
- Chief executive officerBobak R. Azamian Oct 15, 2020 to now12
- ChairBobak R. Azamian Dec 16, 2022 to now13
- PresidentBobak R. Azamian Oct 15, 2020 to now12
- Chief financial officerLeonard M. Greenstein Oct 15, 2020 to Apr 21, 202314
- Chief operating officerSeshadri Neervannan Oct 15, 2020 to now15
Board members and other officers (19)
- Chief Medical OfficerElizabeth Yeu Lin Nov 6, 2024 to now16
- OfficerJeffrey S. Farrow Apr 26, 2023 to now17
- CHIEF MEDICAL OFFICERJose M. Trevejo Feb 3, 2022 to Dec 22, 202318
- Chief Human Resources OfficerDianne C. Whitfield Jan 8, 2021 to now19
- Chief Commercial OfficerAziz Mottiwala Oct 15, 2020 to now20
- V.P., Clinical AffairsMark J. Holdbrook Oct 15, 2020 to Mar 21, 202321
- Board memberDavid E. I. Pyott Feb 20, 2026 to now22
- Board memberKatherine Goodrich Nov 15, 2024 to now23
- Board memberElizabeth Yeu Lin Jan 4, 2022 to Jun 25, 202424
- Board memberScott W. Morrison Oct 11, 2022 to now25
- Board memberRosemary A. Crane Aug 12, 2021 to Jun 25, 202426
- Board memberAndrew D. Goldberg Oct 15, 2020 to now27
- Board memberBhaskar Chaudhuri Oct 15, 2020 to now28
- Board memberBobak R. Azamian Oct 15, 2020 to Nov 18, 202212
- Board memberJason E. Tester Oct 15, 2020 to Jun 17, 202129
- Board memberMichael Ackermann Oct 15, 2020 to Jul 1, 202230
- Board memberWilliam J. Link Phd. Oct 15, 2020 to now31
- Board memberWendy L. Yarno Nov 23, 2020 to now32
- General counselBryan Wahl Jan 21, 2021 to now33
Timeline
- Oct 13, 20268-K Financial statements and exhibits34
- Sep 10, 20268-K Completed an acquisition or sale; Other events35
- Aug 6, 20268-K Entered a material agreement; Unregistered sale of shares; Other events36
- Aug 6, 20268-K Entered a material agreement; Unregistered sale of shares; Other events37
- Aug 6, 20268-K Results of operations38
- Jul 13, 20268-K Executive or director change39
- Jul 8, 20268-K Entered a material agreement; Unregistered sale of shares; Other events40
- Jun 29, 20268-K Shareholder vote41
- May 6, 20268-K Results of operations42
- Feb 23, 20268-K Results of operations43
- Feb 18, 20268-K Executive or director change44
- Jan 12, 20268-K Regulation FD disclosure45
- Oct 15, 2020New chief executive Bobak R. Azamian becomes CEO12
Calendar
Coming up
- Nov 3, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.30) a share, on Nov 4, 2025.46
When it reported results
- Aug 6, 2026Reported quarterly or annual results38
- May 6, 2026Reported quarterly or annual results42
- Feb 23, 2026Reported quarterly or annual results43
- Nov 4, 2025Reported quarterly or annual results47
- Aug 6, 2025Reported quarterly or annual results48
- May 1, 2025Reported quarterly or annual results49
- Feb 25, 2025Reported quarterly or annual results50
- Nov 13, 2024Reported quarterly or annual results51
Drug trials and FDA: coming up
- Dec 31, 2026Phase 2 trial readout expected Phase 2 trial of lotilaner and Vehicle in Ocular Rosacea: primary completion expected Dec 31, 2026 (ClinicalTrials.gov NCT07443202).52
- Oct 2027Phase 2 trial readout expected Phase 2 trial of TP-05 (lotilaner) Low Dose and TP-05 (lotilaner) High Dose in Lyme Disease: primary completion expected Oct 2027 (ClinicalTrials.gov NCT07562087).53
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar
Filings
567 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 60 major events, 275 insider forms, 51 large holders, 161 other. The latest 20:
- Oct 13, 20268-K/A EDGAR
- Oct 13, 2026S-3ASR EDGAR
- Oct 13, 2026S-3ASR EDGAR
- Sep 17, 20264 EDGAR
- Sep 17, 20264 EDGAR
- Sep 17, 20264 EDGAR
- Sep 15, 2026144 EDGAR
- Sep 10, 20268-K EDGAR
- Sep 9, 20264 EDGAR
- Sep 9, 20264 EDGAR
- Sep 9, 20264 EDGAR
- Sep 4, 2026144 EDGAR
- Sep 4, 2026144 EDGAR
- Sep 4, 2026144 EDGAR
- Sep 4, 2026144 EDGAR
- Sep 3, 20264 EDGAR
- Sep 3, 20264 EDGAR
- Sep 2, 2026144 EDGAR
- Sep 2, 2026144 EDGAR
- Sep 2, 2026144 EDGAR
The 567 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
199 open-market trades by officers, directors and large owners since October 2021: 4 buys and 195 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | LINK WILLIAM J PHDDirector | Sale | 12,500 | $78.38 | $979.7K | Form 4 |
| Sep 4, 2026 | Lin Elizabeth YeuChief Medical Officer | Sale | 13,953 | $87.50 | $1.2M | Form 4 |
| Sep 4, 2026 | Azamian Bobak R.President/CEO and Board Chair | Sale | 10,000 | $90.56 | $905.6K | Form 4 |
| Sep 4, 2026 | Neervannan SeshadriChief Operating Officer | Sale | 4,564 | $85.00 | $387.9K | Form 4 |
| Sep 2, 2026 | Lin Elizabeth YeuChief Medical Officer | Sale | 6,977 | $80.00 | $558.2K | Form 4 |
| Sep 2, 2026 | Azamian Bobak R.President/CEO and Board Chair | Sale | 10,000 | $80.06 | $800.6K | Form 4 |
| Sep 1, 2026 | Lin Elizabeth YeuChief Medical Officer | Sale | 4,601 | $73.86 | $339.8K | Form 4 |
| Jun 17, 2026 | Azamian Bobak R.President/CEO and Board Chair | Sale | 10,000 | $61.55 | $615.5K | Form 4 |
| Jun 16, 2026 | Farrow Jeffrey SSee Remarks | Sale | 14,396 | $60.95 | $877.4K | Form 4 |
| Jun 15, 2026 | Goodrich KatherineDirector | Sale | 2,954 | $62.08 | $183.4K | Form 4 |
| Jun 15, 2026 | LINK WILLIAM J PHDDirector | Sale | 12,500 | $62.12 | $776.5K | Form 4 |
| Mar 20, 2026 | Neervannan SeshadriChief Operating Officer | Sale | 2,989 | $66.75 | $199.5K | Form 4 |
| Mar 19, 2026 | Lin Elizabeth YeuChief Medical Officer | Sale | 390 | $67.00 | $26.1K | Form 4 |
| Mar 19, 2026 | Wahl BryanGeneral Counsel | Sale | 4,231 | $67.00 | $283.5K | Form 4 |
| Mar 19, 2026 | Whitfield Dianne C.Chief Human Resources Officer | Sale | 4,174 | $67.00 | $279.7K | Form 4 |
| Mar 19, 2026 | Azamian Bobak R.President/CEO and Board Chair | Sale | 11,964 | $67.00 | $801.6K | Form 4 |
| Mar 19, 2026 | Neervannan SeshadriChief Operating Officer | Sale | 4,589 | $67.00 | $307.5K | Form 4 |
| Mar 19, 2026 | Mottiwala AzizChief Commercial Officer | Sale | 4,440 | $67.00 | $297.5K | Form 4 |
| Mar 19, 2026 | Farrow Jeffrey SSee Remarks | Sale | 2,186 | $67.00 | $146.5K | Form 4 |
| Mar 18, 2026 | Lin Elizabeth YeuChief Medical Officer | Sale | 379 | $68.71 | $26.0K | Form 4 |
All 199 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Janus Henderson Group Ltd.SCHEDULE 13G/A, 2 filings May 15, 2026 to Aug 13, 202654
- Deep Track Capital, LPSCHEDULE 13G/A, 3 filings Jul 28, 2025 to May 15, 202655
- Prudential FinancialSCHEDULE 13G/A, 2 filings Nov 14, 2024 to May 8, 202656
- JENNISON ASSOCIATES LLCSCHEDULE 13G/A, 2 filings Nov 12, 2024 to May 6, 202657
- VANGUARD GROUP INCSCHEDULE 13G/A, 3 filings Nov 4, 2024 to Mar 27, 202658
- TANG CAPITAL MANAGEMENT LLCSCHEDULE 13G/A, 2 filings May 15, 2025 to Feb 17, 202659
- RTW INVESTMENTS, LPSCHEDULE 13G/A, 4 filings Feb 14, 2022 to Aug 14, 202560
- Morgan StanleySCHEDULE 13G/A, 2 filings Feb 9, 2024 to May 7, 202561
- BlackRockSCHEDULE 13G/A, 6 filings Feb 8, 2023 to Apr 24, 202562
- Cowen Financial Products LLCSCHEDULE 13G/A, 3 filings May 5, 2023 to Feb 13, 202563
- Cormorant Asset Management, LPSC 13G/A, 4 filings Feb 14, 2022 to Nov 14, 202464
- Paradigm Biocapital Advisors LPSC 13G/A, 2 filings Jan 22, 2024 to Nov 14, 202465
- Frazier Life Sciences IX, L.P.SC 13G/A, 2 filings Jan 28, 2022 to Nov 6, 202466
- TANG CAPITAL PARTNERS LPSC 13G/A, 3 filings May 13, 2022 to Feb 14, 202467
- Vivo Capital IX, LLCSC 13G/A, 3 filings Feb 11, 2022 to Feb 13, 202468
- TimesSquare Capital Management, LLCSC 13G/A, 2 filings Feb 3, 2023 to Feb 2, 202469
- PERCEPTIVE ADVISORS LLCSC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 202370
- James E. FlynnSC 13G/A, 2 filings May 11, 2022 to Feb 10, 202371
- Bobak R. AzamianSC 13G/A, 1 filing Feb 14, 202272
- Michael AckermannSC 13G/A, 1 filing Feb 14, 202273
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Bobak AzamianM.D., Ph.D. | $726.3K | $6.6M74 | |
| 2025 | Aziz Mottiwala | $529.2K | $2.8M74 | |
| 2025 | Jeffrey Farrow | 64 | $541.7K | $2.7M74 |
| 2025 | Seshadri NeervannanPh.D. | $547.0K | $2.6M74 | |
| 2025 | Bryan Wahl, M.D., J.D. | 48 | $500.8K | $2.6M74 |
| 2024 | PresidentChief Executive Officer and Board Chairman | $673.4K | $7.9M74 | |
| 2024 | Chief Financial Officer and Chief Strategy Officer | $520.8K | $3.2M74 | |
| 2024 | Chief Operating Officer | $527.3K | $3.2M74 | |
| 2024 | Chief Commercial Officer | $492.6K | $3.1M74 | |
| 2023 | Chief Financial Officer and Chief Strategy Officer | $343.8K | $4.0M74 | |
| 2023 | PresidentChief Executive Officer and Board Chairman | $619.5K | $3.1M74 | |
| 2023 | Chief Operating Officer | $500.0K | $1.7M74 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 3,856,137 | $242.7M | 0.0% | +303,525 |
| Deep Track Capital, LP | 3,666,768 | $230.8M | 3.4% | +66,768 |
| Rtw Investments, LP | 3,357,059 | $211.3M | 1.8% | +11,034 |
| Jupiter Topco LLC | 2,808,796 | $176.8M | 0.1% | New |
| Paradigm Biocapital Advisors LP | 2,775,649 | $174.7M | 3.3% | +213,495 |
| Assenagon Asset Management S.A. | 1,894,990 | $119.3M | 0.1% | +614,796 |
| Morgan Stanley | 1,827,082 | $115.0M | 0.0% | −117,190 |
| Vanguard Capital Management LLC | 1,793,064 | $112.9M | 0.0% | +32,523 |
| Jennison Associates LLC | 1,663,655 | $104.7M | 0.1% | −48,469 |
| Tang Capital Management LLC | 1,568,266 | $98.7M | 4.5% | +379,642 |
| Millennium Management LLC | 1,427,124 | $89.8M | 0.1% | +862,545 |
| Bank Of America Corp /de/ | 1,193,182 | $75.1M | 0.0% | −1,195 |
| Geode Capital Management, LLC | 1,105,689 | $69.6M | 0.0% | −15,402 |
| State Street Corp | 1,072,951 | $67.5M | 0.0% | +94,739 |
| Vestal Point Capital, LP | 1,050,000 | $66.1M | 1.5% | +850,000 |
| Invesco Ltd. | 785,808 | $49.5M | 0.0% | +43,311 |
| Goldman Sachs Group Inc | 742,693 | $46.7M | 0.0% | +303,067 |
| Frazier Life Sciences Management, L.P. | 728,644 | $45.9M | 1.0% | No change |
| D. E. Shaw & Co., Inc. | 710,559 | $44.7M | 0.0% | −80,587 |
| Fmr LLC | 672,949 | $42.4M | 0.0% | −60,385 |
| Nomura Asset Management International Inc. | 607,272 | $38.2M | 0.1% | +107,419 |
| Clearbridge Investments, LLC | 549,387 | $34.6M | 0.0% | +4,036 |
| Toronto Dominion Bank | 510,253 | $32.1M | 0.1% | No change |
| Massachusetts Financial Services Co /ma/ | 427,008 | $26.9M | 0.0% | New |
| Northern Trust Corp | 386,611 | $24.3M | 0.0% | +33,654 |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How Tarsus Pharmaceuticals, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARTarsus Pharmaceuticals, Inc.1
- CIK0001819790
- Employer ID (EIN)81-47178613
- Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company3
- Incorporated inDelaware3
- Fiscal year endsDecember 311
- Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address15440 Laguna Canyon Road, Irvine, CA 926181
- Phone(949) 409-98201
- Shares outstanding43,882,996 as of Jul 30, 202610
- Public float$1.7B as of Jun 30, 20253
- AuditorErnst & Young LLP, Irvine, California PCAOB ID 42; it also attests to the company’s internal control over financial reporting3
- On EDGAR sinceAug 7, 20201
- Filings671 in all: 4 (303), 144 (118), 8-K (70), SC 13G/A (28), 3 (24), SC 13G (19), 10-Q (18), SCHEDULE 13G/A (12)1
All 35 form types
424B5 (8), CORRESP (8), S-8 (7), UPLOAD (7), 10-K (6), DEF 14A (6), DEFA14A (6), ARS (4), EFFECT (3), S-3ASR (3), DRS/A (2), S-3 (2), SCHEDULE 13G (2), SEC STAFF LETTER (2), 144/A (1), 3/A (1), 424B4 (1), 8-A12B (1), 8-K/A (1), CERT (1), DRS (1), DRSLTR (1), FWP (1), S-1 (1), S-1/A (1), S-1MEF (1), SC 13D (1)
- Latest filingsAnnual report (10-K) Feb 23, 2026
Quarterly report (10-Q) Aug 6, 2026
Proxy statement (DEF 14A) Apr 28, 2026
Latest 8-K (8-K) Sep 10, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, $0.0001 par value per share | TARS | Nasdaq Global Select Market |
From the cover page of the 10-K filed Feb 23, 2026 (Section 12(b) of the Exchange Act).3
Risk factors and legal proceedings
The risks Tarsus Pharmaceuticals, Inc. names in Item 1A of its 10-K filed Feb 23, 2026: 73 risks under these headings, as written.3
- Risks Related to our Business and Operations
- We are a commercial stage biopharmaceutical company with a limited operating history and a single product approved for commercial sale. While we have generated revenue from the launch of XDEMVY® (lotilaner ophthalmic solution) 0.25%, we have continued to incur losses and negative cash flows from operations since our inception and anticipate that we could continue to incur significant expenses and potential losses in the future.
- We expect to expand our development, regulatory, operational, sales, marketing, and distribution capabilities and, as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.
- Our future success depends on our ability to retain key employees, consultants and advisors and to attract, retain and motivate qualified personnel.
- Our information technology systems, or those of our third-party contract research organizations (“CROs”) or other contractors or consultants, may fail or suffer security breaches, loss or leakage of data, and other disruptions, which could result in a material disruption of XDEMVY and our product candidates’ development programs, compromise sensitive information related to our business or prevent us from accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business.
- Product liability lawsuits against us could cause us to incur substantial liabilities, could divert our resources and could limit or delay our commercialization of XDEMVY or any product candidates that we may develop.
- Our employees, independent contractors, including our CROs and CMOs, commercial partners, consultants, suppliers, service providers, and other vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have an adverse effect on our results of operations.
- Unfavorable global and geopolitical economic conditions could adversely affect our business, financial condition or results of operations.
- Health epidemics may affect our ability to initiate and complete preclinical studies and clinical trials, disrupt regulatory activities, disrupt our manufacturing and supply chain or have other adverse effects on our business and operations. In addition, health epidemics could cause substantial disruption in the financial markets and may adversely impact economies worldwide, both of which could result in adverse effects on our business and operations.
- We or the third parties upon whom we depend on may be adversely affected by earthquakes, fires or other natural disasters, or geopolitical events and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.
- Risks Related to Development and Commercialization
- We obtained regulatory approval for XDEMVY in the U.S. in July 2023 and commenced the commercial launch of XDEMVY in August 2023. We have limited experience as a commercial company and generating revenue from product sales. If the commercialization of XDEMVY becomes unsuccessful or any future approved product launches are unsuccessful, our ability to become or remain profitable may be unsuccessful.
The other 63 risks
- We are heavily dependent on the continued successful commercialization of XDEMVY and the successful development, regulatory approvals, and commercialization of our current and future product candidates.
- We may not ultimately be successful in educating ECPs and the market about the need for treatments specifically for Demodex blepharitis and other diseases or conditions targeted by XDEMVY or our product candidates. XDEMVY or other product candidates that we may develop may fail to achieve market acceptance by ECPs, other healthcare providers and patients, or adequate formulary coverage, pricing or reimbursement by third-party payers and others in the medical community, and the market opportunity for these products may be smaller than we estimate.
- The sales, marketing, and distribution of XDEMVY or any future approved products may be unsuccessful or less successful than anticipated. If we are unable to establish sales and marketing capabilities for any of our future approved products or enter into agreements with third parties to sell and market XDEMVY or any future approved products on acceptable terms, we may be unable to continue to successfully commercialize XDEMVY or successfully commercialize any future approved products.
- The sizes of the market opportunities for our product or product candidates, particularly XDEMVY for the treatment of Demodex blepharitis, may be smaller than we estimate, possibly materially. If we overestimate the size of these markets, our sales growth may be adversely affected. We may also not be able to grow the markets for our product candidates as intended or at all.
- We may face significant potential competition in the future, and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer or less expensive than the product candidates we develop, our commercial opportunities will be negatively impacted. XDEMVY and our product candidates, if approved, will also compete with existing branded, generic and off-label products.
- Although we obtained FDA approval of XDEMVY, and even if we obtain FDA approval of any of our product candidates, we may never obtain approval or authorization for such product candidates, including XDEMVY, in any other jurisdiction or commercialize such product candidates in the U.S. or in any other jurisdiction, which would limit our ability to realize their full market potential.
- Our future product candidates may cause significant adverse events, toxicities or other undesirable side effects which may delay or prevent marketing approval or cause us to abandon or limit further clinical development or commercialization of those product candidates. In addition, significant adverse events, toxicities or other undesirable side effects may be identified during post-marketing surveillance for XDEMVY, or future approved products, which could result in regulatory action or negatively affect our ability to market the product.
- As we participate in the Medicaid Drug Rebate Program and other governmental pricing programs, failure to comply with obligations under these programs could result in additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.
- We may expend our limited resources on the commercialization of XDEMVY for the treatment of Demodex blepharitis and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.
- The terms of approvals and ongoing regulation of XDEMVY and any other current product candidates or product candidates we develop could require substantial expenditure of resources and may limit how we manufacture and market our products, which could materially impair our ability to generate revenue from product sales.
- If XDEMVY or any of our product candidates that are approved for marketing are found to have been improperly promoted for off-label uses by us, or if ECPs misuse our products or use our products off-label, we may become subject to prohibitions
- on the sale or marketing of our products, product liability claims and significant fines, penalties and sanctions, and our brand and reputation could be harmed.
- Clinical drug development is a lengthy, expensive and risky process with uncertain timelines and uncertain outcomes, and results of earlier studies and trials may not be predictive of future results. If clinical trials of our product candidates do not meet safety or efficacy endpoints or are prolonged or delayed, we may be unable to obtain required regulatory approvals, and therefore be unable to commercialize our product candidates on a timely basis or at all.
- Our product candidates still require significant testing. We only recently began clinical trials to test TP-04 and TP-05 in humans and, as a company, we have limited experience in this area.
- We have and may continue to encounter difficulties or delays enrolling patients in our clinical trials, which could cause delays in or adverse effects of our clinical development activities.
- Any termination or suspension of, or delays in the commencement or completion of, our planned clinical trials could result in increased costs to us, delay or limit our ability to generate revenue from product sales and adversely affect our commercial prospects.
- Our future growth may depend, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.
- We have conducted a number of our completed clinical trials and may conduct ongoing clinical trials for our product candidates at sites outside the U.S., and the FDA may not accept data from trials conducted in such locations.
- Managing our obligations under our in-license and out-license agreements and other strategic agreements may divert management time and attention, causing delays or disruptions to our business.
- Our operating activities may be restricted by certain covenants in our license and other strategic agreements, which could limit our development and commercial opportunities.
- Interim top-line and preliminary results from our clinical trials that we announce or publish from time to time may change as more participant data become available and are subject to audit and verification procedures, which could result in material changes in the final data.
- Risks Related to our Financial Position and Need for Additional Capital
- Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.
- Due to the ongoing commercialization of XDEMVY and our continued development of our pipeline of product candidates through clinical trials and other indications, our capital requirements are difficult to predict and may change. We may need to obtain additional funding to achieve our goals and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, reduce or eliminate our product development programs, commercialization efforts or other operations.
- Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.
- Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults or non-performance by financial institutions or transactional counterparties, could adversely affect our business and our financial condition and results of operations.
- Our existing indebtedness may limit our flexibility in financing and operating our business and adversely affect our business, financial condition and results of operations.
- We may engage in acquisitions or strategic partnerships that could disrupt our business, cause dilution to our stockholders, reduce our financial resources, cause us to incur debt or assume contingent liabilities, and subject us to other risks.
- Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.
- We may be subject to adverse legislative or regulatory tax changes that could negatively impact our financial condition.
- Risks Related to Reliance on Third Parties
- We rely on third parties to conduct our clinical trials and perform some of our research and preclinical studies. If these third parties do not satisfactorily carry out their contractual duties or fail to meet expected deadlines, our development programs may be delayed or subject to increased costs, each of which may have an adverse effect on our business and prospects.
- We, or our third-party manufacturers, may be unable to successfully scale-up manufacturing of XDEMVY or our product candidates in sufficient quality and quantity, which would delay or prevent us from commercializing, conducting clinical trials and developing our product candidates.
- Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.
- Risks Related to Intellectual Property
- Changes in patent law in the U.S. and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect XDEMVY or our product candidates.
- The development and commercialization of our product, or our product candidates, including XDEMVY for the treatment of Demodex blepharitis, TP-04 for the potential treatment of ocular rosacea, and TP-05 for potential Lyme disease prophylaxis and community malaria reduction, is dependent on intellectual property we license from Elanco. If we breach our agreements with Elanco or the agreements are terminated, we could lose license rights that are important to our business.
- If we are unable to obtain and maintain sufficient intellectual property protection for XDEMVY or our product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be adversely affected.
- Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
- We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent which might adversely affect our ability to develop and market our products.
- We may wish to acquire rights to future assets through in-licensing or may attempt to form collaborations in the future with respect to XDEMVY or our product candidates, but may not be able to do so, which may cause us to alter or delay our commercialization or development plans.
- In the future, we may need to obtain additional licenses of third-party technology that may not be available to us or are available only on commercially unreasonable terms or we may fail to comply with our obligations under such agreements and our business could be harmed.
- We cannot ensure that patent rights relating to inventions described and claimed in our pending patent applications will issue or that our patents or patents based on our patent applications will not be challenged and rendered invalid and/or unenforceable.
- If we are sued for infringing, misappropriating or otherwise violating intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our product candidates.
- If we do not obtain patent term extension for any product candidates we may develop, our business may be materially harmed.
- We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time-consuming and unsuccessful.
- Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties.
- We may not be able to protect our intellectual property rights throughout the world.
- We may rely on trade secret and proprietary know how which can be difficult to trace and enforce, and if we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
- We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.
- Intellectual property rights do not necessarily address all potential threats to our competitive advantage.
- Patent terms may be inadequate to protect our competitive position on our product candidates and preclinical programs for an adequate amount of time.
- Risks Related to Government Regulation
- Our industry is highly regulated by the FDA and comparable foreign regulatory authorities. We must comply with extensive, strictly enforced regulatory requirements to develop, obtain, and maintain marketing approval for XDEMVY or any of our product candidates, if approved.
- Changes in healthcare law and implementing regulations, as well as changes in healthcare policy, may impact our business in ways that we cannot currently predict, and may have a significant adverse effect on our business and results of operations.
- Our direct-to-consumer marketing and telehealth pilot program may be subject to increased regulatory scrutiny.
- Our employees, independent contractors, clinical trial investigators, CROs, consultants, vendors and any potential commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.
- If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.
- We may be subject to federal, state and foreign healthcare and abuse laws and false claims laws, as well as information privacy and security laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could
- face substantial penalties, criminal sanctions, contractual damages, reputational harm, and diminished profits and future earnings.
- Inadequate funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
- We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations.
- For XDEMVY, or if we receive marketing approval for another product candidate, we are and will continue being subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and subject us to restrictions, withdrawal from the market, or penalties if we fail to comply with applicable regulatory requirements or if we experience unanticipated problems with our product candidates, when and if approved.
- Failure to comply with health and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), significant fines, private litigation, and/or adverse publicity and could negatively affect our financial condition, operating results and business.
- Risks Related to Ownership of our Common Stock
- The stock price of our common stock may be volatile or may decline regardless of our operating performance and you could lose all or part of your investment.
- If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.
- Sales of a substantial number of shares of our common stock in the public market could cause the price of our common stock to fall.
Legal proceedings
We are not currently a party to any material legal proceedings. From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors.
The opening of Item 3, Legal Proceedings.3
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13SEC EDGARBobak R. Azamian, Chair
- 14
- 15
- 16
- 17SEC EDGARJeffrey S. Farrow, Officer
- 18
- 19
- 20
- 21
- 22SEC EDGARDavid E. I. Pyott, Board member
- 23SEC EDGARKatherine Goodrich, Board member
- 24SEC EDGARElizabeth Yeu Lin, Board member
- 25SEC EDGARScott W. Morrison, Board member
- 26SEC EDGARRosemary A. Crane, Board member
- 27SEC EDGARAndrew D. Goldberg, Board member
- 28SEC EDGARBhaskar Chaudhuri, Board member
- 29SEC EDGARJason E. Tester, Board member
- 30SEC EDGARMichael Ackermann, Board member
- 31SEC EDGARWilliam J. Link Phd., Board member
- 32SEC EDGARWendy L. Yarno, Board member
- 33SEC EDGARBryan Wahl, General counsel
- 34SEC EDGARFinancial statements and exhibits
- 35
- 36
- 37
- 38SEC EDGARResults of operations
- 39SEC EDGARExecutive or director change
- 40
- 41SEC EDGARShareholder vote
- 42SEC EDGARResults of operations
- 43SEC EDGARResults of operations
- 44SEC EDGARExecutive or director change
- 45SEC EDGARRegulation FD disclosure
- 46NasdaqNasdaq calendar
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74